CAR-T Cell Therapy for Diverse Disease Treatment
Legal Citation
Summary of the Inventive Concept
The inventive concept leverages the core technology of CAR-T cells with TCM as the main active component to treat various diseases beyond the original application, including respiratory, cardiovascular, neurodegenerative, inflammatory, and autoimmune diseases.
Background and Problem Solved
The original patent disclosed a method for preparing CAR-T cells with TCM as the main active component. However, the patent's scope was limited to a specific application. This inventive concept addresses the limitation by applying the core technology to diverse disease areas, providing a novel solution for unmet medical needs.
Detailed Description of the Inventive Concept
The inventive concept involves administering CAR-T cells with TCM as the main active component to patients in need of treatment for various diseases. The TCM is targeted to specific antigens associated with the respective diseases. This approach enables the CAR-T cells to selectively target and eliminate disease-causing cells, offering a promising therapeutic strategy. The system and composition embodiments encompass various administration routes, dosing regimens, and antigen targets, ensuring flexibility and adaptability across different disease indications.
Novelty and Inventive Step
The new claims introduce a significant inventive step by expanding the application of CAR-T cells with TCM beyond the original scope, demonstrating a non-obvious connection between the core technology and the newly targeted disease areas.
Alternative Embodiments and Variations
Alternative embodiments may involve modifying the CAR-T cell composition, such as using different antigen targets or incorporating additional therapeutic molecules. Variations may include combining the CAR-T cell therapy with other treatment modalities, like chemotherapy or gene therapy, to enhance therapeutic efficacy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with a target market encompassing various disease areas, including respiratory, cardiovascular, neurodegenerative, inflammatory, and autoimmune diseases. The market size is substantial, with an estimated value in the billions of dollars.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, specifically CAR-T cell engineering and therapeutic applications, with expertise in cell biology, immunology, and targeted cellular therapies
Person of Ordinary Skill (PHOSITA) Profile
A researcher or clinician with advanced degrees in biomedical sciences, experienced in genetic engineering of T cells, understanding of cellular immunology, and knowledge of chimeric antigen receptor (CAR) design and therapeutic targeting strategies
Obviousness Rationale
A PHOSITA would recognize that the core CAR-T cell technology with central memory T cells (TCM) represents a versatile platform technology that can be readily adapted to target different disease-specific antigens. The fundamental mechanism of selectively targeting and eliminating disease-causing cells through engineered CAR-T cells is a predictable approach that can be systematically applied across multiple disease domains. The PTD demonstrates a straightforward extension of the source patent's core technological principles by simply retargeting the existing CAR-T cell platform to different antigen profiles.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,572 |
|---|---|
| Title | Method for preparing CAR-T cell with TCM as main active component and use thereof |
| Assignee(s) | Xuanwu Hospital Capital Medical University |